CN1381281A - Introduced suppository for magnetotherapy or thermotherapy and its application method - Google Patents
Introduced suppository for magnetotherapy or thermotherapy and its application method Download PDFInfo
- Publication number
- CN1381281A CN1381281A CN 02118225 CN02118225A CN1381281A CN 1381281 A CN1381281 A CN 1381281A CN 02118225 CN02118225 CN 02118225 CN 02118225 A CN02118225 A CN 02118225A CN 1381281 A CN1381281 A CN 1381281A
- Authority
- CN
- China
- Prior art keywords
- suppository
- thermotherapy
- magnetotherapy
- tumor
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000829 suppository Substances 0.000 title claims description 35
- 238000000015 thermotherapy Methods 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 58
- 239000002245 particle Substances 0.000 claims abstract description 22
- 230000005294 ferromagnetic effect Effects 0.000 claims abstract description 19
- 208000005189 Embolism Diseases 0.000 claims abstract description 15
- 230000005291 magnetic effect Effects 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 14
- 208000001435 Thromboembolism Diseases 0.000 claims description 13
- 239000000956 alloy Substances 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000005684 electric field Effects 0.000 claims description 5
- 230000010102 embolization Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 239000000696 magnetic material Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000000704 physical effect Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000005672 electromagnetic field Effects 0.000 abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- LLXOATMJZSVSII-UHFFFAOYSA-N 2-[[1-(4-hydroxy-3-iodophenyl)-3-oxopyrrolidine-2-carbonyl]amino]ethyl 2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=CC(C=2C(=CC=CC=2)C(F)(F)F)C=1C(=O)OCCNC(=O)C(C(CC1)=O)N1C1=CC=C(O)C(I)=C1 LLXOATMJZSVSII-UHFFFAOYSA-N 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 239000004531 microgranule Substances 0.000 description 19
- 229910045601 alloy Inorganic materials 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000005389 magnetism Effects 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 230000005415 magnetization Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229910000815 supermalloy Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Thermotherapy And Cooling Therapy Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
An intervening embolism agent for magnetothermal therapy is tumor features that the ferromagnetic particles carried by the intervening embolism agent are introduced to the tumor tissue, the iodipin is used as guide to distribute the said ferromagnetic particles in the tumor tissue, and an external high-frequency alternate electromagnetic field is applied to them for generating induced heat to make tumor tissue to be solidfied and necrotic.
Description
The invention belongs to the tumor thermotherapy technical field, be specifically related to a kind of introduced suppository for magnetotherapy or thermotherapy and using method thereof.
Present therapies such as most single employing radio frequency, ultrasound wave, microwave in the thermotherapy technical field of tumor, these therapies all have some identical defectives, first: normal structure and tumor tissues are all had the heat damage effect, can not effectively tumor tissues and normal tissue well be differentiated, and it is limited to the destruction at tumor tissues edge, mainly be that the borderline tumor part compares with normal structure, the situation of being heated is close, does not often reach the treatment temperature.So the recurrence after the thermotherapy of tumor all occurs in the edge of tumor tissues.Second: blood vessel structure in the tumor tissues and the microcirculation tumor vessel net system that compares with normal structure is congenital bad and the tumor vessel neural sensor is unsound, to such an extent as to tumor tissues can not can be taken away more heat as the blood vessel in the normal structure to greatest extent in heating, but tumor vessel still can be taken away the part heat and makes the heating of tumor tissues is failed to reach fully optimal boundary.The tumor intervention therapeutic technology provides comparatively ideal method at the blood supplier face to the blocking-up tumor now, and in the topical therapeutic of tumor, obtained gratifying achievements, but it also has an apparent in view weak point: liquefaction and necrosis takes place in the center of tumor tissues, and often there is the existence of remaining focus at the edge of tumor tissues, and it is more common particularly not having this situation of tumor of peplos.
The objective of the invention is to provide a kind of and can be effectively the interventional therapeutic technique of the thermotherapy of tumor and tumor be combined, and help insertion thermotherapy suppository and the using method that big institute of traditional Chinese medicine uses at the deficiencies in the prior art.This suppository not only has tip suppository commonly used thromboembolism effect to the tumor tissues peripheral vessel, and it can also be converted into iron loss with the energy major part that adds alternating electromagnetic field, produces a large amount of heat energy.Purpose of the present invention can realize in the following manner that introduced suppository for magnetotherapy or thermotherapy is suspended in the thromboembolism carrier by surfactant by the ferromagnetic particle of diameter less than 5 microns.Using method is: utilize the interventional technique super-selective that introduced suppository for magnetotherapy or thermotherapy is injected the supply vessels of tumor, pass to alternating magnetic field (or electric field) external, and make tumor tissues can place to greatest extent among the alternating magnetic field (or electric field).
Microgranule in the aforesaid introduced suppository for magnetotherapy or thermotherapy, it can process by soft magnetic material or by retentive material, and is big with pcrmeability, resistance is little, specific loss big (being that iron loss is big) is for good.If use retentive material then after interventional embolization, external high-intensity magnetic field is magnetized, make it have stronger remanent magnetism.No matter be after interventional embolization, all can directly externally pass to the high frequency alternating electromagnetic field by the suppository that soft magnetic material or retentive material make to give eddy-current heating.If make then can be at the external strong static magnetic field of giving earlier with the retentive material microgranule in suppository magnetization, again at the external high frequency alternating electromagnetic field that passes to but microgranule is a retentive material.This is because the retentive material microgranule has very strong remanent magnetism after the strong static magnetic field magnetization, passing to alternating electromagnetic field this moment, the hard magnetic microgranule not only can be owing to iron loss produces heat, microgranule will produce violent vibration under the effect of alternating magnetic field, acutely rub with the molecule around it, produce a large amount of heat energy.
The diameter of aforesaid ferromagnetic particle should because help the microgranule of macrophage removing thromboembolism in nonneoplastic tissue less than the microgranule of 5 micron diameters, and reduce the microcirculatory influence of normal structure as far as possible less than 5 microns.The diameter of ferromagnetic particle is to be best less than 20 nanometers, because the microgranule of size can be got rid of external within a certain period of time like this.
Aforesaid ferromagnetic particle, its material can be to adopt the alloy material of Curie's shop temperature lower (50-60 degree centigrade) to constitute.When tissue temperature rises to the Curie-point temperature of alloy, the alloy permeability descends suddenly and loses magnetism, the ability that it absorbs outside magnetic energy will significantly reduce, thereby heat production significantly reduces, and drop to curie point when following when tissue temperature, pcrmeability recovers, and alloy particle absorbs a large amount of magnetic energy again and is converted to heat energy, continues as the tumor tissues heating.The temperature of its heating just can obtain automatic adjusting to a certain extent like this.
It must have the better tissues compatibility with tissue aforesaid ferromagnetic particle, if it has certain toxicity in medium-term and long-term delay of tissue, then the surface of ferromagnetic particle should wrap by the nontoxic sealing coat of one deck with ferromagnetic particle with organize isolated.This layer sealing coat can be gold, silver, organic membrane etc.
It can be that the surfactant of self-faced active substance or synthetic or both have both at the same time for aforesaid surfactant.The effect of surfactant has: 1. the particle aggregation that overcomes Van der Waals for and caused; 2. change the character on alloy particle surface, make that microgranule and base fluid are muddy to be integral.The requirement total to surfactant be, an end of activating agent can be adsorbed in microparticle surfaces, forms very strong chemical bond, the other end can with the thromboembolism carrier solventization.
Thromboembolism carrier in the aforesaid introduced suppository for magnetotherapy or thermotherapy, it is good with the tip suppository, is good with the suppository with tumor vessel guide effect especially in the tip suppository, as iodized oil.Its benefit is that 1. enter tumor tissues by tumor vascular siphonage selectivity; 2. lack mononuclear phagocyte system and lymphatic return System Cleaning iodized oil granule and ferromagnetic particle wherein in the tumor tissues; 3. because normal structure has perfect scavenging system, can the short time can be with iodized oil and ferromagnetic particle wherein by removings such as monokaryon macrophage and skein cell, endotheliocytes.In alternating electromagnetic field, normal structure is got involved hardly, and tumor tissues is heated by high specific.
Thromboembolism carrier in the aforesaid introduced suppository for magnetotherapy or thermotherapy, it can be the carrier that contains chemicals, effectively thermotherapy and chemotherapy technology is combined.It also can contain nanometer guide medicine (chemical medicine, physical property medicine etc.).Carrier also can contain some can be responded to and help the used material of external thermometric by external instrument.
Aforesaid alternating electromagnetic field, it can be a high-frequency alternating magnetic field, also can be alternating electric field.If but the ferromagnetic particle in the suppository is the retentive material microgranule then is good with alternating magnetic field, because the retentive material microgranule can produce very intensive vibration and produce a large amount of heat energy with violent friction of molecule generation on every side in alternating magnetic field, its use is simultaneously generally magnetized the retentive material microgranule in the suppository at the external strong static magnetic field of giving earlier, again at the external high frequency alternating electromagnetic field that passes to.This is that passing to alternating electromagnetic field this moment because the retentive material microgranule has very strong remanent magnetism after the strong static magnetic field magnetization, and the effect of heating will be better than unmagnetized microgranule.The invention has the advantages that:
1, the present invention fully arrives tumor by local thermotherapy and intervention embolization effective connection together.
2, because people's physical ability is born very strong magnetostatic field, so very safe ready ground fully magnetizes the permanent-magnet alloy microgranule of thromboembolism in tumor tissues.
3, since the permanent-magnet alloy microgranule compare with tissue and have very strong eddy-current loss, obviously produce more thermal energy so contain the tumor tissues of a large amount of permanent-magnet alloy microgranules than normal structure, the heat energy that produces can't be taken away because of the thromboembolism of blood vessel, heat energy is further accumulated, to make the tumor tissues temperature of comparing with normal structure obviously raise, and can reach the needed temperature of tumor coagulation necrosis easily.Obviously reduced influence during such benefit to normal structure.
4, since the most of thromboembolism of permanent-magnet alloy microgranule in the capillary network of the tumor edge of tumor tissues particularly, such consequence is that the lip temperature of tumor tissues is obviously higher, destroy and obviously increase the weight of, the deficiency that can remedy tumor thermotherapy technology and interventional technique is promptly: the center to tumor tissues is destroyed obviously, but can not destroy the borderline tumor tissue up hill and dale effectively.And benefit of the present invention is exactly to destroy the edge of tumor tissues more up hill and dale.
5, owing to can just can improve the temperature of tumor tissues heating, owing to the conduction of temperature and then can enlarge destructive zone by suitable enhancing alternating magnetic field intensity.Such benefit is to make the present invention to the wettability tumor curative effect preferably be arranged, and can change intervention embolization to the wettability tumor situation of unsatisfactory curative effect often.
6 because the thromboembolism carrier among the present invention can be some tip suppositories with blood vessel guidance quality, as iodized oil etc., just make this introduced suppository for magnetotherapy or thermotherapy that tumor group is woven with higher specificity, thereby make the present invention have more specificity the heating of tumor tissues.
Now a pair of in conjunction with the embodiments the present invention is further elaborated:
Nanoparticle 8 grams of the supermalloy (49% ferrum, 49% cobalt, 2% vanadium) of diameter 10-20 nanometer are suspended among the iodized oil with poly-third ethylene of artificial synthetic high molecular surfactant, and this suspension is the introduced suppository for magnetotherapy or thermotherapy among the present invention.This suspension is injected blood supply of tumor by the intervening mode super-selective.Again at the external alternating magnetic field that passes to frequency 27.12MHz.
Now two the present invention is further elaborated in conjunction with the embodiments:
Nanoparticle 8 grams of the aluminum steel of diameter 10-20 nanometer are suspended among the iodized oil with poly-third ethylene of artificial synthetic high molecular surfactant, and this suspension is the introduced suppository for magnetotherapy or thermotherapy among the present invention.This suspension is injected blood supply of tumor by the intervening mode super-selective.The external again magnetostatic field that passes to intensity 3T 5 minutes fully magnetizes the hard magnetic material microgranule in the suppository, again at the external high-frequency alternating magnetic field that passes to frequency 27.12MHz.
Claims (8)
1. introduced suppository for magnetotherapy or thermotherapy is characterized in that: be suspended in the thromboembolism carrier and the suspension that is exclusively used in the tumor intervention embolization that forms by means of surfactant less than 5 microns ferromagnetic particles.
2. introduced suppository for magnetotherapy or thermotherapy as claimed in claim 1 is characterized in that: ferromagnetic particle can process by soft magnetic material or by retentive material, and is big with pcrmeability, resistance is little, specific loss big (being that iron loss is big) is for good.
3. introduced suppository for magnetotherapy or thermotherapy as claimed in claim 1 is characterized in that: the diameter of ferromagnetic particle is being the best less than 20 nanometers.
4. introduced suppository for magnetotherapy or thermotherapy as claimed in claim 1 is characterized in that: ferromagnetic particle can be to adopt the alloy material of Curie's shop temperature lower (50-60 degree centigrade) to make.
5. introduced suppository for magnetotherapy or thermotherapy as claimed in claim 1, it is characterized in that: it must have the better tissues compatibility with tissue ferromagnetic particle, if it has certain toxicity in medium-term and long-term delay of tissue, then the surface of ferromagnetic particle should wrap by the nontoxic sealing coat of one deck with ferromagnetic particle with organize isolatedly, this layer sealing coat can be gold, silver, organic membrane etc.
6. introduced suppository for magnetotherapy or thermotherapy as claimed in claim 1 is characterized in that: the thromboembolism carrier is good with the tip suppository, is good with the suppository with tumor vessel guide effect especially in the tip suppository.
7. introduced suppository for magnetotherapy or thermotherapy as claimed in claim 1 is characterized in that: the thromboembolism carrier can be the carrier that contains chemicals, effectively thermotherapy and chemotherapy technology is combined; It also can contain nanometer guide medicine (chemical medicine, physical property medicine etc.); Carrier also can contain some can be responded to and help the used material of external thermometric by external instrument.
8. the using method of introduced suppository for magnetotherapy or thermotherapy as claimed in claim 1, it is characterized in that: utilize the interventional technique super-selective introduced suppository for magnetotherapy or thermotherapy to be injected the supply vessels of tumor, pass to alternating magnetic field (or electric field) external, and make tumor tissues can place to greatest extent among the alternating magnetic field (or electric field).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02118225 CN1381281A (en) | 2002-04-26 | 2002-04-26 | Introduced suppository for magnetotherapy or thermotherapy and its application method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02118225 CN1381281A (en) | 2002-04-26 | 2002-04-26 | Introduced suppository for magnetotherapy or thermotherapy and its application method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1381281A true CN1381281A (en) | 2002-11-27 |
Family
ID=4744618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02118225 Pending CN1381281A (en) | 2002-04-26 | 2002-04-26 | Introduced suppository for magnetotherapy or thermotherapy and its application method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1381281A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330387C (en) * | 2005-02-07 | 2007-08-08 | 武汉理工大学 | Magnetic combine powder type vessel embolizing material |
| US10842550B2 (en) | 2017-10-13 | 2020-11-24 | Jen-Jie Chieh | Non-invasive thermal ablation device and method |
-
2002
- 2002-04-26 CN CN 02118225 patent/CN1381281A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330387C (en) * | 2005-02-07 | 2007-08-08 | 武汉理工大学 | Magnetic combine powder type vessel embolizing material |
| US10842550B2 (en) | 2017-10-13 | 2020-11-24 | Jen-Jie Chieh | Non-invasive thermal ablation device and method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rivas et al. | Magnetic nanoparticles for application in cancer therapy | |
| Rajan et al. | Review on magnetic nanoparticle-mediated hyperthermia for cancer therapy | |
| Chan et al. | Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer | |
| JP4410560B2 (en) | Nanoscale magnetic compound | |
| Esmaeili et al. | Preparation of ZnFe2O4–chitosan-doxorubicin hydrochloride nanoparticles and investigation of their hyperthermic heat-generating characteristics | |
| Roca et al. | Iron oxide nanoparticles (Fe3O4, γ-Fe2O3 and FeO) as photothermal heat mediators in the first, second and third biological windows | |
| Lin et al. | Application of nanosized Fe3O4 in anticancer drug carriers with target-orientation and sustained-release properties | |
| Shetake et al. | Magnetic hyperthermia therapy: An emerging modality of cancer treatment in combination with radiotherapy | |
| US20140249351A1 (en) | Microparticles for selectively targeted hyperthermia | |
| CN102056563A (en) | Nanoparticle-mediated microwave treatment methods | |
| Bossmann et al. | Magnetic nanomaterials: Applications in catalysis and life sciences | |
| Hedayatnasab et al. | Investigation properties of superparamagnetic nanoparticles and magnetic field-dependent hyperthermia therapy | |
| CN107661499B (en) | Preparation method of magnetic induction thermotherapy embolism microsphere | |
| EP1509206A4 (en) | A hemostatic composition | |
| CN1381281A (en) | Introduced suppository for magnetotherapy or thermotherapy and its application method | |
| Fatmawati et al. | Synthesis methods of Fe3O4 nanoparticles for biomedical applications | |
| CN105903013A (en) | A kind of Fe3O4 nanoparticle aggregate and its preparation method | |
| CN202105321U (en) | Magnetic nanoparticle magnetic induction thermal focusing system based on compound magnetic field | |
| JPH09328438A (en) | Medical powder | |
| Tiwari et al. | The combined effect of thermal and chemotherapy on HeLa cells using magnetically actuated smart textured fibrous system | |
| Sun et al. | Combination using magnetic iron oxide nanoparticles and magnetic field for cancer therapy | |
| CN116459386B (en) | Silver-loaded nano titanium dioxide modified polydopamine photo-thermal antibacterial hydrogel and preparation method thereof | |
| CN106315684A (en) | Preparation method of size-controllable spherical MnZn ferrite magnetic nanoparticles | |
| Ramanujan et al. | Magnetic particles for hyperthermia treatment of cancer | |
| JP2017521454A (en) | Tumor treatment method with metal fullerene single crystal nanoparticles selectively destroying tumor blood vessels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LI LI Effective date: 20050805 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20050805 Address after: 641300 five sets of West Village, Yanjiang Town, Yanjiang District, Sichuan, Ziyang Applicant after: Zhang Jun Co-applicant after: Li Li Address before: 641300 five sets of West Village, Yanjiang Town, Yanjiang District, Sichuan, Ziyang Applicant before: Zhang Jun |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |